JP2005523329A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523329A5
JP2005523329A5 JP2003587152A JP2003587152A JP2005523329A5 JP 2005523329 A5 JP2005523329 A5 JP 2005523329A5 JP 2003587152 A JP2003587152 A JP 2003587152A JP 2003587152 A JP2003587152 A JP 2003587152A JP 2005523329 A5 JP2005523329 A5 JP 2005523329A5
Authority
JP
Japan
Prior art keywords
glycyl
preparation according
aqueous preparation
alkali metal
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003587152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523329A (ja
JP3927954B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2003/004745 external-priority patent/WO2003086471A2/en
Publication of JP2005523329A publication Critical patent/JP2005523329A/ja
Publication of JP2005523329A5 publication Critical patent/JP2005523329A5/ja
Application granted granted Critical
Publication of JP3927954B2 publication Critical patent/JP3927954B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003587152A 2002-04-16 2003-04-15 カンプトテシン誘導体含有水性製剤およびそれを凍結乾燥した医薬組成物 Expired - Fee Related JP3927954B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16
PCT/JP2003/004745 WO2003086471A2 (en) 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Publications (3)

Publication Number Publication Date
JP2005523329A JP2005523329A (ja) 2005-08-04
JP2005523329A5 true JP2005523329A5 (enExample) 2006-04-13
JP3927954B2 JP3927954B2 (ja) 2007-06-13

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003587152A Expired - Fee Related JP3927954B2 (ja) 2002-04-16 2003-04-15 カンプトテシン誘導体含有水性製剤およびそれを凍結乾燥した医薬組成物

Country Status (21)

Country Link
US (1) US20050215485A1 (enExample)
EP (1) EP1501549A2 (enExample)
JP (1) JP3927954B2 (enExample)
KR (1) KR100700963B1 (enExample)
CN (1) CN100544769C (enExample)
AR (1) AR039272A1 (enExample)
AU (1) AU2003223120B2 (enExample)
BR (1) BR0309283A (enExample)
CA (1) CA2480425A1 (enExample)
HR (1) HRP20040894A2 (enExample)
ME (1) MEP31308A (enExample)
MX (1) MXPA04010178A (enExample)
MY (1) MY136696A (enExample)
NO (1) NO20044964L (enExample)
PL (1) PL371677A1 (enExample)
RS (1) RS91204A (enExample)
RU (1) RU2315623C2 (enExample)
TW (1) TW200306314A (enExample)
UA (1) UA77295C2 (enExample)
WO (1) WO2003086471A2 (enExample)
ZA (1) ZA200408008B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714653B1 (en) * 2004-02-13 2010-11-24 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing a camptothecin
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
CA2612949C (en) 2005-07-14 2015-04-28 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
WO2013011598A1 (ja) * 2011-07-15 2013-01-24 コニカミノルタホールディングス株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
CN113304278A (zh) 2014-12-26 2021-08-27 日本化药株式会社 喜树碱类高分子衍生物的药物制剂
RU2726415C2 (ru) 2015-09-03 2020-07-14 Ниппон Каяку Кабусики Каися Фармацевтическая композиция, содержащая полимерное производное камптотецина
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
RU2018129760A (ru) * 2016-03-01 2020-04-01 Ниппон Каяку Кабусики Кайся Фармацевтический препарат, содержащий полимерное производное на основе камптотецина
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
MX2024006239A (es) * 2021-11-26 2024-06-11 Astellas Pharma Inc Composicion farmaceutica solida que contiene el compuesto indocianina.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
DK0540099T3 (da) * 1991-10-29 1996-06-17 Glaxo Wellcome Inc Vandopløselige camptothecinderivater
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
AU2001271037A1 (en) * 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Similar Documents

Publication Publication Date Title
JP5936546B2 (ja) 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミドのメグルミン塩
US11759497B2 (en) Daptomycin formulations
JPWO2012043700A1 (ja) 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミドのナトリウム塩
KR100546450B1 (ko) 약학 조성물
CA2341568A1 (en) Stabilized pharmaceutical composition in lyophilized form
PT1988913E (pt) Formulação líquida de g-csf
JP6461945B2 (ja) ある含有量のマイトマイシンcを有する凍結乾燥医薬組成物を製造する方法
JPH1129497A5 (enExample)
JP7043156B2 (ja) ベンゾアゼピン化合物含有凍結乾燥組成物
JP2006137678A (ja) インターロイキン−2組成物
JP3927954B2 (ja) カンプトテシン誘導体含有水性製剤およびそれを凍結乾燥した医薬組成物
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
JPWO1999036065A1 (ja) 医薬組成物
TWI242447B (en) An injectable pharmaceutical compositions of dalfopristine/quinupristine combination
UA59376C2 (uk) Стабілізована фармацевтична композиція на основі хінупристину та дальфопристину та спосіб її одержання
JP2002201137A (ja) ビダラビン注射用乾燥製剤
JPH05967A (ja) 組織プラスミノーゲンアクチベーター含有製剤組成物
HK40063745B (en) Benzoazepine compound-containing freeze-dried composition
JPH01156925A (ja) ネオカルチノスタチン誘導体の凍結乾操製剤組成物
JPH0710753A (ja) 注射剤
JP2018095593A (ja) 凍結乾燥製剤及びその製造方法
HK1183014B (en) Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
JPWO1998043643A1 (ja) アシクロビル水溶液製剤